CLINICAL STAGING IN MULTIPLE-MYELOMA

被引：66

作者：

WOODRUFF, RK

WADSWORTH, J

MALPAS, JS

TOBIAS, JS

机构：

[1] IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON WC2A 3PX,ENGLAND

[2] ST BARTHOLOMEWS HOSP,COMP MED SCI UNIT,LONDON EC1A 7BE,ENGLAND

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1979年 / 42卷 / 02期

关键词：

D O I：

10.1111/j.1365-2141.1979.tb01124.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Summary. Analysis of 237 patients with myeloma, retrospectively classified according to the staging system proposed by Durie and Salmon, showed highly significant differences (P < 0.0001) in the survival of patients with low, intermediate and high tumour cell masses (Stages I, II and III respectively). The median survival for Stage I patients was 64 months, Stage II 32 months, and Stage III 6 months. The median survival of patients presenting with renal impairment was only 2 months, compared to 21 months for those presenting with normal renal function (P < 0.0001). The use of this clinical staging system, which is based on myeloma protein synthesis rates and the calculation of total body tumour cell mass, should be considered in planning future trials of therapy in this disease. Copyright © 1979, Wiley Blackwell. All rights reserved

引用

页码：199 / 205

页数：7

共 12 条

[1]

ALEXANIAN R, 1975, CANCER, V36, P1192, DOI 10.1002/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO

[2]

2-I

[3] PLASMACYTIC MYELOMA - A STUDY OF RELATIONSHIP OF SURVIVAL TO VARIOUS CLINICAL MANIFESTATIONS AND ANOMALOUS PROTEIN TYPE IN 112 PATIENTS [J].